USPH Q3: Adjusted EPS Beats at $0.80, But Revenue Falls Short of $214.5M
USPH sits 62% above its 52-week low of $58.19.
Summary
Adjusted earnings came in at 80 cents a share, four cents above the 76-cent consensus and up from 66 cents a year ago. Revenue is the problem: $197.52 million, up only 0.2% year over year and well short of the $214.54 million analysts expected. The GAAP line shows a $1.04 loss per share, continuing the pattern of non-cash revaluation charges that also drove the Q1 loss, while net income was $11.05 million. Estimates had already been drifting lower — the mean EPS estimate fell about 5.4% over three months and one analyst cut in the past 30 days — so the beat is against a lowered bar. This follows the Dow Jones report of the $1.04 GAAP loss earlier tonight; the revenue miss is the piece that matters for the thesis.
At the time of this announcement, USPH was trading at $94.00 on NYSE in the Life Sciences sector, with a market capitalization of approximately $1.3B. The 52-week trading range was $58.19 to $90.94. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Reuters.